PharmatrophiX and Circular Genomics have partnered to advance blood-based circular RNA biomarkers in neurodegenerative drug development programmes. This collaboration aims to enhance the understanding and treatment of neurodegenerative diseases through innovative biomarker research.
The partnership may provide new insights into the mechanisms of these diseases, potentially leading to more effective therapeutic strategies. For manufacturers and suppliers in the biotech sector, this collaboration highlights the growing importance of biomarker-driven approaches in drug development, which could influence future research and investment priorities.
Source: pharmaceutical-technology.com · Image: NIH- Unidentified Laboratory Photos (CC0)
Start your 7-day trial and see what the database can do →